Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Avalo Therapeutics Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates August 12, 2024 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer July 16, 2024 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa July 09, 2024 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer June 24, 2024 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit June 17, 2024 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates May 13, 2024 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Therapeutics Appoints Biotech Leaders to Board of Directors April 02, 2024 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX TRML Avalo Reports 2023 Financial Results and Provides Business Updates March 29, 2024 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million March 27, 2024 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX SLRN Avalo Therapeutics Announces 1-for-240 Reverse Stock Split December 27, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split December 07, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates November 09, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation September 26, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX HRZN Avalo Enters into Agreement to Divest AVTX-800 Series September 12, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 06, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates August 03, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo to Participate in SVB Securities Therapeutics Forum July 06, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma June 26, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo to Present at the Jefferies Healthcare Conference June 01, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board May 22, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo to Present at ATS 2023 Respiratory Innovation Summit May 15, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference May 10, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates May 04, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Reports 2022 Financial Results and Provides Business Updates March 29, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference March 07, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants February 02, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants February 02, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma January 17, 2023 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates November 07, 2022 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million November 07, 2022 From Avalo Therapeutics Via GlobeNewswire Tickers AVTX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.